State Street’s HCW Biologics HCWB Stock Holding History

State Street’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-89	Closed	-$6.05K	–	4289
2025 Q1	$6.05K	Hold	89	–	–	﹤0.01%	4267
2024 Q4	$9.57K	Hold	89	–	–	﹤0.01%	4280
2024 Q3	$11.6K	Hold	89	–	–	﹤0.01%	4256
2024 Q2	$13.9K	Hold	89	–	–	﹤0.01%	4309
2024 Q1	$35.8K	Hold	89	–	–	﹤0.01%	4209
2023 Q4	$26.3K	Hold	89	–	–	﹤0.01%	4310
2023 Q3	$41K	Hold	89	–	–	﹤0.01%	4332
2023 Q2	$46.5K	Hold	89	–	–	﹤0.01%	4437
2023 Q1	$29.6K	Hold	89	–	–	﹤0.01%	4626
2022 Q4	$41.2K	Hold	89	–	–	﹤0.01%	4600
2022 Q3	$49K	Hold	89	–	–	﹤0.01%	4661
2022 Q2	$47K	Buy	89 +3	+3%	+$1.69K	﹤0.01%	4735
2022 Q1	$56K	Buy	86 +2	+2%	+$1.07K	﹤0.01%	4777
2021 Q4	$47K	Buy	+84	New	+$57.1K	﹤0.01%	4709

Other funds holding HCWB

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

State Street's HCWB Position: Q2 2025 in Review

State Street sold out of HCW Biologics (HCWB) in Q2 2025, closing a stake of 89 shares — an estimated $6.05K sold.

State Street first reported a position in HCWB in Q4 2021 and held it in 14 quarters. The position peaked at $56K in Q1 2022. 8 funds tracked by Wall St. Rank hold HCWB as of Q2 2025.

State Street reported no remaining HCW Biologics position as of Q2 2025 after selling out during the quarter.
State Street sold 89 HCW Biologics shares in Q2 2025, an estimated $6.05K.
State Street first reported a position in HCW Biologics in Q4 2021 and held it in 14 quarters.
State Street's HCW Biologics position peaked at $56K in Q1 2022.
8 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2025.

Based on State Street's 13F filing for Q2 2025, filed 14 Aug 2025.